Patents by Inventor William V. Murray

William V. Murray has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chemically modified quinoline and quinolone derivatives useful as CB-1 inverse agonists
    Patent number: 9815790
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the CB1 receptor. Such compounds are represented by Formula (I) wherein R1, R2, R3, L1, n, v, r, w, and g are defined herein. and further represented by Formula (II) wherein the group “X?Y”, ring A, R10, R11, R30, W, and t are defined herein.
    Type: Grant
    Filed: August 17, 2016
    Date of Patent: November 14, 2017
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark J. Macielag, Yue-Mei Zhang, Michael N. Greco, Barry A. Springer, William V. Murray
  • CHEMICALLY MODIFIED QUINOLINE AND QUINOLONE DERIVATIVES USEFUL AS CB-1 INVERSE AGONISTS
    Publication number: 20170057922
    Abstract: Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the CB1 receptor. Such compounds are represented by Formula (I) wherein R1, R2, R3, L1, n, v, r, w, and g are defined herein. and further represented by Formula (II) wherein the group “X?Y”, ring A, R10, R11, R30, W, and t are defined herein.
    Type: Application
    Filed: August 17, 2016
    Publication date: March 2, 2017
    Applicant: Janssen Pharmaceutica NV
    Inventors: Mark J. Macielag, Yue-Mei Zhang, Michael N. Greco, Barry A. Springer, William V. Murray
  • Substituted amino acids as erythropoietin mimetics
    Patent number: 7384979
    Abstract: This invention relates to a series of substitituted amino acids of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention are small molecules which bind to the erythropoietin receptor and compete with the natural ligand for binding to this receptor.
    Type: Grant
    Filed: May 30, 2006
    Date of Patent: June 10, 2008
    Assignee: Ortho McNeil Pharmaceutical, Inc.
    Inventors: Peter J. Connolly, William V. Murray, Steven K. Wetter, Sigmond Johnson, Victor T. Bandurco, Jacqueline Bussolari
  • NON-PEPTIDIC NPY Y2 RECEPTOR INHIBITORS
    Publication number: 20080132540
    Abstract: The invention provides novel non-peptidic NPY Y2 receptor inhibitors useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a neurotrophic factor; neurological disorders; bone loss; substance related disorders; obesity; or an obesity-related disorder. Compounds of the invention are also useful in modulating endocrine functions, particularly endocrine functions controlled by the pituitary and hypothalamic glands, and are therefore useful in the treatment or prevention of inovulation and infertility.
    Type: Application
    Filed: November 19, 2007
    Publication date: June 5, 2008
    Inventors: Nicholas I. Carruthers, Wenying Chai, Scott L. Dax, Jill A. Jablonowski, Xiaobing Li, Timothy W. Lovenberg, William V. Murray, Dale A. Rudolph, Mark Seierstad, Mark A. Youngman
  • Non-peptidic NPY Y2 receptor inhibitors
    Patent number: 7317025
    Abstract: The invention provides novel non-peptidic NPY Y2 receptor inhibitors useful in treating or preventing: anxiolytic disorders or depression; injured mammalian nerve tissue; conditions responsive to treatment through administration of a neurotrophic factor; neurological disorders; bone loss; substance related disorders; obesity; or an obesity-related disorder. Compounds of the invention are also useful in modulating endocrine functions, particularly endocrine functions controlled by the pituitary and hypothalamic glands, and are therefore useful in the treatment or prevention of inovulation and infertility.
    Type: Grant
    Filed: September 24, 2004
    Date of Patent: January 8, 2008
    Assignee: Johnson & Johnson Pharmaceutical Research & Development, LLC
    Inventors: Nicholas I. Carruthers, Wenying Chai, Scott L. Dax, Jill A. Jablonowski, Xiaobing Li, Timothy W. Lovenberg, William V. Murray, Dale A. Rudolph, Mark Seierstad, Mark A. Youngman
  • Cyclohexyl derivatives as selective estrogen receptor modulators
    Patent number: 7183445
    Abstract: The present invention is directed to novel cyclohexyl derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and diseases mediated by an estrogen receptor.
    Type: Grant
    Filed: June 1, 2004
    Date of Patent: February 27, 2007
    Assignee: Janssen Pharmaceutica N.V
    Inventors: Nareshkumar F. Jain, Mark J. Macielag, William V. Murray, Raymond A. Ng, Zhihua Sui
  • Substituted amino acids as erythropoietin mimetics
    Patent number: 7153869
    Abstract: This invention relates to a series of substitituted amino acids of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention are small molecules which bind to the erythropoietin receptor and compete with the natural ligand for binding to this receptor.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: December 26, 2006
    Inventors: Peter J. Connolly, Victor T. Bandurco, Steven K. Wetter, Sigmond Johnson, Jacqueline Bussolari, William V. Murray
  • Heterocycles useful in the treatment of benign prostatic hyperplasia
    Patent number: 6841682
    Abstract: This invention relates a to a series of heterocyclic substituted piperazines of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the ?-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this disease.
    Type: Grant
    Filed: November 26, 2001
    Date of Patent: January 11, 2005
    Assignee: Janseen Pharmaceutica N.V.
    Inventors: Richard H. Hutchings, Haripada Khatuya, Gee-Hong Kuo, Xiaobing Li, William V. Murray, Catherine Prouty, Frank Villani, Nelson C. F. Yim, Cynthia Maryanoff
  • Substituted amino acids as erythropoietin mimetics
    Publication number: 20040248815
    Abstract: This invention relates to a series of substitituted amino acids of Formula I 1
    Type: Application
    Filed: March 12, 2004
    Publication date: December 9, 2004
    Applicant: Ortho McNeil Pharmaceutical, Inc.
    Inventors: Peter J. Connolly, Victor T. Bandurco, Steven K. Wetter, Sigmond Johnson, Jacqueline Bussolari, William V. Murray
  • Macroheterocylic compounds useful as kinase inhibitors
    Patent number: 6828327
    Abstract: This invention is directed to macroheterocyclic compounds useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.
    Type: Grant
    Filed: December 6, 2001
    Date of Patent: December 7, 2004
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Gee-Hong Kuo, Han-Cheng Zhang, Catherine Prouty, Alan DeAngelis, Peter Connolly, William V. Murray, Lan Shen, Bruce Conway, Keith Demarest, Chandra R. Shah, Bruce E. Maryanoff, Kimberly B. White
  • Phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia
    Patent number: 6780994
    Abstract: This invention relates to a series of heterocyclic substituted piperazines of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the &agr;-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this disease.
    Type: Grant
    Filed: July 29, 2002
    Date of Patent: August 24, 2004
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Gee-Hong Kuo, William V. Murray, Catherine P. Prouty
  • Substituted amino acids as erythropoietin mimetics
    Patent number: 6750369
    Abstract: This invention relates to a series of substituted amino acids of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention are small molecules which bind to the erythropoietin receptor and compete with the natural ligand for binding to this receptor.
    Type: Grant
    Filed: August 10, 2001
    Date of Patent: June 15, 2004
    Assignee: Ortho McNeil Pharmaceutical, Inc.
    Inventors: Peter J. Connolly, Victor T. Bandurco, Steven K. Wetter, Sigmond Johnson, Jacqueline Bussolari, William V. Murray
  • Methods for the synthesis of highly substituted 2,4-dioxopiperidine libraries
    Patent number: 6686503
    Abstract: The invention relates to methods of synthesizing libraries of diverse and complex highly substituted 2,4-dioxopiperidine compounds of the general formula: wherein R1, R2 and R3 are as herein described, novel intermediates useful for synthesizing such 2,4-dioxopiperidine compounds and methods for identifying and isolating the compounds.
    Type: Grant
    Filed: June 13, 2001
    Date of Patent: February 3, 2004
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Wenying Chai, William V. Murray
  • Methods for the synthesis of complex reduced isoindole, isooxyindole and isooxyquinoline libraries
    Patent number: 6667406
    Abstract: Disclosed are methods of synthesizing libraries of diverse complex hexahydroisoindole, hexahydroisooxyindole and octahydroisooxyquinoline compounds through the use of a facile intramolecular Diels Alder reaction. The invention is further directed to methods for synthesizing the libraries on solid supports. The invention is further directed to methods for identifying and isolating such hexahydroisoindole, hexahydroisooxyindole and octahydroisooxyquinoline compounds with useful and diverse activities from such libraries.
    Type: Grant
    Filed: March 7, 2000
    Date of Patent: December 23, 2003
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Sengen Sun, William V. Murray
  • Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia
    Publication number: 20030088099
    Abstract: This invention relates to a series of heterocyclic substituted piperazines of Formula I 1
    Type: Application
    Filed: July 29, 2002
    Publication date: May 8, 2003
    Inventors: Gee-Hong Kuo, William V. Murray, Catherine P. Prouty
  • Macroheterocylic compounds useful as kinase inhibitors
    Publication number: 20030078280
    Abstract: This invention is directed to macroheterocyclic compounds useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or ameliorating a kinase or dual-kinase mediated disorder.
    Type: Application
    Filed: December 6, 2001
    Publication date: April 24, 2003
    Inventors: Gee-Hong Kuo, Han-Cheng Zhang, Catherine Prouty, Alan DeAngelis, Peter Connolly, William V. Murray, Lan Shen, Bruce Conway, Keith Demarest, Chandra R. Shah, Bruce E. Maryanoff, Kimberly B. White
  • Methods for the synthesis of densely functionalized pyrrolidine intermediates
    Patent number: 6512120
    Abstract: This invention is directed to methods of synthesizing densely functionalized pyrrolidine compounds through the use of intramolecular Diels Alder reactions.
    Type: Grant
    Filed: March 12, 2002
    Date of Patent: January 28, 2003
    Assignee: Ortho McNeil Pharmaceutical, Inc.
    Inventors: Pranab Mishra, Sengen Sun, William V. Murray
  • Novel heterocycles useful in the treatment of benign prostatic hyperplasia
    Publication number: 20020165219
    Abstract: This invention relates a to a series of heterocyclic substituted piperazines of Formula I 1
    Type: Application
    Filed: November 26, 2001
    Publication date: November 7, 2002
    Inventors: Richard H. Hutchings, Haripada Khatuya, Gee-Hong Kuo, Xiaobing Li, William V. Murray, Catherine Prouty, Frank Villani, Nelson C.F. Yim, Cynthia Maryanoff
  • Novel phthalimido arylpiperazines useful in the treatment of benign prostatic hyperplasia
    Publication number: 20020077476
    Abstract: This invention relates to a series of heterocyclic substituted piperazines of Formula I 1
    Type: Application
    Filed: December 11, 2001
    Publication date: June 20, 2002
    Inventors: Gee-Hong Kuo, William V. Murray, Catherine P. Prouty
  • Heterocycles useful in the treatment of benign prostatic hyperplasia
    Patent number: 6384035
    Abstract: This invention relates a to a series of heterocyclic substituted piperazines of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention selectively inhibit binding to the &agr;-1a adrenergic receptor, a receptor which has been implicated in benign prostatic hyperplasia. As such the compounds are potentially useful in the treatment of this disease.
    Type: Grant
    Filed: October 9, 1998
    Date of Patent: May 7, 2002
    Assignee: Ortho-McNeil Pharmaceutical, Inc.
    Inventors: Richard H. Hutchings, Haripada Khatuya, Gee-Hong Kuo, Xiaobing Li, William V. Murray, Catherine Prouty, Frank Villani, Nelson C. F. Yim, Cynthia Maryanoff